Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Banque Transatlantique SA has invested approximately $278,000 in Immunocore Holdings PLC by purchasing 10,150 shares in the first quarter.
• Several other institutional investors have also increased their stakes in Immunocore, with Barclays PLC growing its holdings by an astounding 2,044% during the previous quarter.
• Immunocore reported a 30% increase in revenue year-over-year, totaling $130.65 million for the last quarter, and beat earnings per share estimates slightly.

Banque Transatlantique SA bought a new stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,150 shares of the company's stock, valued at approximately $278,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new position in Immunocore in the 4th quarter valued at approximately $25,000. Oppenheimer Asset Management Inc. purchased a new position in Immunocore in the 1st quarter valued at approximately $225,000. Tema Etfs LLC purchased a new position in Immunocore in the 4th quarter valued at approximately $330,000. GAMMA Investing LLC boosted its position in Immunocore by 3,318.1% in the 1st quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock valued at $5,670,000 after buying an additional 18,548 shares during the period. Finally, Barclays PLC boosted its position in Immunocore by 2,044.0% in the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after buying an additional 19,663 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

IMCR traded down $0.28 on Wednesday, reaching $36.31. The company had a trading volume of 83,785 shares, compared to its average volume of 333,734. Immunocore Holdings PLC Sponsored ADR has a 1 year low of $23.15 and a 1 year high of $39.33. The stock has a market capitalization of $1.83 billion, a PE ratio of -90.39 and a beta of 0.77. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. The stock has a 50-day moving average price of $33.80 and a 200-day moving average price of $31.65.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm had revenue of $130.65 million during the quarter, compared to analysts' expectations of $122.96 million. During the same period in the previous year, the company earned ($0.23) earnings per share. Immunocore's quarterly revenue was up 30.0% compared to the same quarter last year. As a group, research analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a research report on Tuesday, May 27th. They set a "buy" rating and a $65.00 price objective for the company. Jefferies Financial Group assumed coverage on Immunocore in a research report on Monday, August 25th. They set a "buy" rating and a $48.00 price objective for the company. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 4th. HC Wainwright restated a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday, June 2nd. Finally, Wall Street Zen lowered shares of Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Immunocore has a consensus rating of "Hold" and an average price target of $56.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.